Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-Part Phase 1 Study to Evaluate the Potential Drug-Drug Interactions Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel-Ethinyl Estradiol-Containing Oral Contraceptives, and Carbamazepine in Healthy Adult Participants

Trial Profile

A Three-Part Phase 1 Study to Evaluate the Potential Drug-Drug Interactions Between Vemircopan and Rosuvastatin, Metformin, Levonorgestrel-Ethinyl Estradiol-Containing Oral Contraceptives, and Carbamazepine in Healthy Adult Participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbamazepine (Primary) ; Ethinylestradiol/levonorgestrel (Primary) ; Metformin (Primary) ; Rosuvastatin (Primary) ; Vemircopan (Primary)
  • Indications Autoimmune disorders; IgA nephropathy; Lupus nephritis; Myasthenia gravis; Paroxysmal nocturnal haemoglobinuria
  • Focus Pharmacokinetics
  • Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

  • 14 May 2024 Status changed from recruiting to completed.
  • 07 Mar 2024 Planned End Date changed from 18 Mar 2024 to 22 Mar 2024.
  • 07 Mar 2024 Planned primary completion date changed from 18 Mar 2024 to 22 Mar 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top